Fig. 2i–ii.
Cumulative incidence plots for both parts of the composite endpoint. i Time to HbA1c ≥ 8% and reduction < 0.5% since previous visit. ii Time to substantial intensification* of insulin or OAD treatment. Aalen–Johansen plots, with death as a competing risk factor. *Substantial intensification of insulin or OAD defined as: start of new OAD; start of insulin; increase in insulin dose ≥ 10 units; or addition of mealtime bolus insulin to basal insulin or a shift from basal insulin to premixed insulin. HbA1c glycated haemoglobin, OAD oral antihyperglycaemic drug